Clinical trials: Oncologic Diseases
Metastatic Breast Cancer
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer
This is an open-label, three-part, multiple-dose study to evaluate safety, tolerability, and efficacy of U3-1402 in patients with HER3-positive metastatic breast cancer.
- Trial name
- NCT02980341
- Testing
- Patritumab Deruxtecan
- Where
- 26 sites in United States, Japan
- Volunteers
- 182 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Carcinoma In Situ, Current Smoker
Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices
This phase II trial studies how well smoking cessation treatment plans work in tobacco-dependent cancer patients when delivered virtually as part of their cancer care in community oncology practices.
- Conditions
- Carcinoma In Situ, Current Smoker, Malignant Neoplasm, Primary Neoplasm
- Trial name
- NCT03808818
- Testing
- Behavioral, Psychological or Informational Intervention, Nicotine Replacement, Quality-of-Life Assessment
- Where
- 42 sites in United States
- Volunteers
- 306 people, healthy volunteers welcome
- Sponsor
- ECOG-ACRIN Cancer Research Group
Solid Tumor, Lymphoma
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the…
- Trial name
- NCT03884556
- Testing
- TTX-030, Pembrolizumab, Gemcitabine
- Where
- 16 sites in United States
- Volunteers
- 56 people
- Sponsor
- Trishula Therapeutics, Inc.
Colorectal Cancer
Initial Testing of a Mobile App Pain Coping Intervention for Outpatient Oncology Settings (PainPac)
PainPac is innovative in its potential to integrate with healthcare systems through electronic medical records (EMRs). PainPac leverages technology to increase patient access to interventions and uses real-time assessment to…
- Trial name
- NCT05686122
- Testing
- PainPac
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Duke University
Advanced Breast Cancer, Metastatic Breast Cancer
A Clinical Trial to Compare Efficacy and Tolerability of Fulvestrant 250mg, 250mg Plus 250mg Loading Regimen and 500mg
This study will assess the relationship between fulvestrant dose and efficacy in postmenopausal women with oestrogen receptor positive advanced breast cancer.
- Trial name
- FINDER II (NCT00313170)
- Testing
- Fulvestrant
- Where
- 34 sites in Belgium, Canada and 6 more
- Volunteers
- 144 people
- Sponsor
- AstraZeneca
Venous Thrombosis
Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy
This is a randomized trial to compare intermittent compression devices with or without post-operative Arixtra (fondaparinux sodium) in women undergoing major abdominal surgery for known or presumed gynecologic malignancies.
- Trial name
- NCT00539942
- Testing
- Arixtra (fondaparinux sodium), Intermittent compression devices (ICD)
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Anemia, Fatigue
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
RATIONALE: Epoetin alfa may cause the body to make more red blood cells. It is used to treat anemia caused by cancer and chemotherapy. It may also help relieve fatigue in patients with anemia.
- Conditions
- Anemia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00258440
- Testing
- Weekly procrit dosing, Interval Dosing
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- OHSU Knight Cancer Institute
Glioblastoma, Gliosarcoma
A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) followed by combination of ABT-414 with adjuvant TMZ prolongs overall survival (OS) among participants with newly…
- Trial name
- Intellance1 (NCT02573324)
- Testing
- Temozolomide, Depatuxizumab mafodotin, Radiation
- Where
- 212 sites in United States, Argentina and 26 more
- Volunteers
- 691 people
- Sponsor
- AbbVie
Lymphoma, Digestive System Diseases
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Incidence of cancer in 75+ years old is 16,500 new cases per year, more than fifty percent of people with cancerThey are very few therapeutic trials dedicated.
- Conditions
- Lymphoma, Digestive System Diseases, Ovarian Diseases, Pulmonary Disease
- Trial name
- PHRC2003 (NCT00210249)
- Where
- 18 sites in France
- Volunteers
- 364 people
- Sponsor
- Institut Bergonié
Non Small Cell Lung Cancer
Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior…
- Trial name
- NCT02197247
- Testing
- Pharmacokinetic sampling - AZD9291, Rifampicin, AZD9291 tablet dosing
- Where
- 18 sites in United States, Netherlands and 4 more
- Volunteers
- 41 people
- Sponsor
- AstraZeneca
Unresectable Metastatic Colo-rectal Cancer
Chemoembolization, Irinotecan Bead, Second Line Chemotherapy Treatment of Unresectable Metastatic Colorectal Cancer
The primary objective of this study is to evaluate the safety and efficacy of Irinotecan Bead in combination with intravenous chemotherapy versus intravenous chemotherapy alone in the treatment of unresectable liver metastases in…
- Trial name
- PARAGON (NCT00816777)
- Testing
- Chemoembolization with irinotecan Bead, Irinotecan
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Generic Devices Consulting, Inc.
Cancer-related Problem/Condition, Ambulatory Care
Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
The purpose of this study is to see if Glad Press 'n Seal works as a moisture barrier for central line that is left in place during ambulatory oncology clinical care.
- Trial name
- NCT01967836
- Testing
- Glad Press 'n Seal
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Maureen T Greene
Prostatic Neoplasms
Targeted Fusion Biopsy of the Prostate
The purpose of this study is to see if using Positron Emission Tomography (PET) scan and transrectal ultrasound (TRUS) guided biopsy together (creating a 3-dimensional ultrasound) will detect prostate cancer more accurately than…
- Trial name
- NCT02744534
- Testing
- FACBC PET-CT Scan, Three-dimensional ultrasound-guided biopsy, Standard transrectal ultrasound (TRUS) guided biopsy
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Emory University
Leukemia, Lymphoma
Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection
The study team will compare hospital length of stay (LOS) and attributable length of stay (ALOS, the LOS attributable to CRI), in a randomized, un-blinded prospective trial utilizing short-dwell ethanol-lock therapy (ELT) (4…
- Conditions
- Leukemia, Lymphoma, Blood Disorders, Solid Tumors
- Trial name
- NCT02095951
- Testing
- Ethanol lock therapy (ELT)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital of Michigan
Autoimmune Diseases, Renal Disorders
Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device
This study will evaluate the use of the AMICUS device in patients where Therapeutic Plasma Exchange (TPE) is prescribed by their physicians.
- Conditions
- Autoimmune Diseases, Renal Disorders, Hematologic Disorders, Oncologic Disorders
- Trial name
- NCT01210716
- Testing
- Therapeutic plasma exchange
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Fenwal, Inc.
Neoplasms
Topical Curcumin for Precancer Cervical Lesions
The purpose of this study is to see if curcumin can reverse a cervical precancerous state by looking at people who have the condition and intervening with a study drug or placebo (an inactive drug), prior to planned therapeutic…
- Trial name
- NCT02944578
- Testing
- Curcumin
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Lisa Flowers
Colorectal Neoplasm
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)
The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.
- Trial name
- NCT03384940
- Testing
- DS-8201a
- Where
- 25 sites in United States, Italy and 3 more
- Volunteers
- 86 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Cancer, Influenza Viral Infections
Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy
The safety and immunogenicity of high dose influenza vaccine has not been studied in young patients receiving chemotherapy. This study will evaluate and compare the immunogenicity and safety of high dose influenza to standard…
- Trial name
- IMMUNE (NCT01666782)
- Testing
- Standard Trivalent Influenza Vaccine, High-Dose Influenza Vaccine
- Where
- 2 sites in United States
- Volunteers
- 105 people
- Sponsor
- Saad Jamshed MD
Epithelial Ovarian Cancer, Fallopian Tube Cancer
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
This is an open label Phase 2, 2-stage, 2-cohort study to evaluate rucaparib in combination with nivolumab in patients with high-grade serous or endometroid ovarian cancer.
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serous Carcinoma
- Trial name
- NCT03824704
- Testing
- Rucaparib, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- pharmaand GmbH
Breast Cancer, Ovarian Cancer
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat metastatic breast, ovarian, endometrial or cervical cancer not responding to standard treatment.
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- NCT00319748
- Testing
- 852A
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota